This Subcommittee is focused on animal and other models of thrombosis and haemostasis and parameters of coagulation and fibrinolysis.

This Subcommittee is focused on all blood flow related issues in thrombosis and haemostasis: from clinical blood flow assays of haemostasis to basic research models.

The SSC Standing Committee responsible for the Bleeding Assessment Tool Repository.

This subcommittee is focused on laboratory and clinical issues related to the use of anticoagulant drugs. It incorporates internists, haematologists, cardiologists, laboratory scientists and is addressed to a large spectrum of specialists.

This Subcommittee is focused on clinical syndromes of thrombosis and haemostasis, parameters of coagulation and fibrinolysis, and the pathology or etiology, diagnosis and treatments by physicians. This information is provided for experimental researchers, physicians for critical care medicine, hematology gynecology and oncology, and for laboratory scientists, and epidemiologists.

The Factor VIII, Factor IX and Rare Coagulation Disorders Subcommittee has the mission of providing a forum for consideration of practical issues related to haemophilia and other rare bleeding disorders, provide state of the art knowledge regarding the diagnosis and management of these disorders, and conduct projects that aim to standardize and harmonize available laboratory evaluation and clinical care measures for the assessment of therapeutic products and clinical outcomes.

This Subcommittee is focused on basic research, physiology, diagnostics and pharmacology of blood coagulation factor XI and the plasma contact system.

This subcommittee is focused on basic research concerning factors that upregulate/downregulate fibrinolysis as well as on clinical research involving the analysis of fibrinolysis-related parameters.

The Guidance Committee is responsible for initiation, review and approval of clinical Guidance publications issued on behalf of the SSC and ISTH.

This Subcommittee is focused on the spectrum of clinical disorders of hemostasis in malignancy, including venous and arterial thromboembolism, and bleeding. The Subcommittee comprises of members from diverse backgrounds and disciplines including hematologists, oncologists, surgeons, pulmonologists, epidemiologists, and translational and basic scientists.

The Subcommittee is focused on addressing clinical issues in pediatric and neonatal thrombosis and hemostasis.

This subcommittee is focused on clinical and laboratory issues related to natural inhibitors of coagulation and factors associated with heritable thrombophilia, including but not restricted to Antithrombin, protein C, protein S and activated protein C resistance with or without factor V Leiden.

The activities of this Subcommittee are focused on immune disorders of platelets including fetal/neonatal alloimmune thrombocytopenia, primary immune thrombocytopenia (ITP), drug-induced thrombocytopenia and heparin-induced thrombocytopenia.

This subcommittee is focused on all aspects of the biology and function of platelets and their role in thrombosis, haemostasis and normal physiology. The SSC incorporates haematologists, cardiologists, laboratory scientists, health professionals and academics.

This subcommittee is focused on promoting knowledge translation and facilitating collaborative research relating to the predictive utility of clinical and biochemical markers of cardiovascular disease and thrombosis

This Committee will be responsible for all functions normally assigned to an Executive/ Nominating Committee, including matters relating to nominations, to long-range planning, programming, and finance. It should maintain a close relationship with the Scientific Subcommittees. The Executive Committee will function in all essential capacities as needed in the interim between meetings of the SSC.

This Subcommittee is focused on basic and translational research related to vascular biology and related (athero)-thrombotic disorders, through the development of biomarkers that require standardization.

The von Willebrand factor (VWF) subcommittee is focused on the genetics, biology and function of VWF and its protease ADAMTS13, its relationship with cells and other molecules and all laboratory and clinical issues related to these processes, with special emphasis on von Willebrand Disease (VWD). This subcommittee incorporates hematologists and laboratory professionals promoting and facilitating collaborative basic and clinical research projects.

This Subcommittee is focused on clinical syndromes of thrombosis and haemostasis and parameters of coagulation and fibrinolysis that are influenced by hormones and incorporates hematologists, obstetricians and gynecologists, laboratory scientists, and epidemiologists.

The aim of the group is to develop an approach to assist in reducing the time to diagnosis of rare platelet and bleeding disorders, by taking advantage of advances in Next generation sequencing (NGS) and selective capture technologies. For this potential to be fully realized, it is essential to develop a publicly accessible database that will provide stable reference DNA sequences with respect to which sequence variants that are known to be associated with rare inherited disorders can be mapped.